Completed PHASE2 INTERVENTIONAL 4-arm NCT00642707

Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

A Phase 2a, Randomized, Double-blind, Placebo Controlled Study of PRO 140 by Subcutaneous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection

Sponsor: CytoDyn, Inc.

Conditions HIV -1 Infection HIV Infections

Interventions PRO 140 (humanized monoclonal antibody to CCR5) Placebo Comparator

Updated 7 times since 2017 Last updated: Dec 14, 2015 Started: Mar 31, 2008 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00642707, this PHASE2 trial focuses on HIV -1 Infection and HIV Infections and remains completed. Sponsored by CytoDyn, Inc., it has been updated 7 times since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CytoDyn, Inc.

Data source: CytoDyn, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tarrytown, United States